The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.

Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.

A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.

Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.

The synthetic lethality specialist licenses in its second ADC in six months.